Liver Disease Management Market Size is valued at USD 26.78 Billion in 2024 and is predicted to reach USD 52.28 Billion by the year 2034 at a 7.1% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:
Liver disease can be acquired (genetic) or caused by liver-harming causes such as viruses (hepatitis A, B, and C) and alcohol usage. Obesity has been connected to liver disease as well. The liver is required for food digestion as well as to regulate the toxicity of chemicals in the body. One of the primary key factors driving the market's growth is the world's growing geriatric population, which is susceptible to various chronic diseases, including liver disease. Changing dietary habits and sedentary lifestyles are driving market expansion. The rising prevalence of fatty liver disease due to excessive cholesterol, obesity, hypertension (high blood pressure), and diabetes is boosting market growth.
Furthermore, significant technological breakthroughs, such as the creation of the bioartificial liver, are driving market expansion. It replaces liver functions with regenerated liver cells and is commonly utilized in individuals with acute liver failure. By this, the quick acceptance of anti-viral medications, safe and efficient in suppressing the hepatitis B virus and lowering the risk of developing cirrhosis and hepatocellular carcinoma, is favorably impacting the market growth. Aside from that, increased research and development (R&D) efforts, significant increases in the healthcare industry, and implementation of different government measures to enhance public health are producing a good outlook for the market.
The liver disease management market is segmented on diagnosis, treatment and end-use. Based on the diagnosis, the market is segmented into endoscopy, imaging, biopsy, and others. Based on treatment, liver disease management market is segmented into anti-viral drugs, targeted therapy, chemotherapy and others. Based on end-use, the liver disease management market is segmented into clinics, hospitals, diagnostics laboratories and others.
The imaging segment is expected to hold a significant share of the market due to an increase in the number of initiatives launched by key companies in the liver disease diagnostics market to create new imaging techniques. Laboratory tests are performed using urine, blood, and other fluid samples to diagnose liver function. Ultrasound, X-ray, Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, and more imaging procedures are available.
Hospitals grabbed the highest revenue share, and it is anticipated that they will continue to hold that position during the anticipated time. Since most patients rely on hospitals with diagnostic testing instruments, hospitals give excellent treatment to patients and enable early identification and diagnosis, enhancing the market for liver disease diagnostics. Furthermore, continued healthcare infrastructure development is expected to improve existing hospital facilities.
The Asia Pacific Liver disease management market is expected to register the highest market share in revenue in the near future. The growing elderly population and increased awareness of the importance of regular check-ups are driving the expansion of the market for liver disease diagnostics in this area. Furthermore, it is expected that regulatory approval of innovative technologies that can be combined with imaging systems would boost regional growth. In addition, North America is projected to grow rapidly in the global Liver disease management market. High R&D investments and prominent players are projected to drive the growth of the region's market for liver disease diagnostics. Furthermore, organizations that supply patients with information about disease diagnosis are projected to boost the expansion of the market for liver disease diagnostics.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 26.78 Billion |
| Revenue Forecast In 2034 | USD 52.28 Billion |
| Growth Rate CAGR | CAGR of 7.1% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Diagnosis, Treatment, End-Use |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Abbott, AbbVie Inc., Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc, Lilly, Merck & Co., Inc, Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Diagnosis
By Treatment
By End-Use
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Liver Disease Management Market Snapshot
Chapter 4. Global Liver Disease Management Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Diagnosis Estimates & Trend Analysis
5.1. by Diagnosis & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Diagnosis:
5.2.1. Endoscopy
5.2.2. Imaging
5.2.3. Biopsy
5.2.4. Others
Chapter 6. Market Segmentation 2: by Treatment Estimates & Trend Analysis
6.1. by Treatment & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Treatment:
6.2.1. Anti-Viral Drugs
6.2.2. Targeted Therapy
6.2.3. Chemotherapy
6.2.4. Others
Chapter 7. Market Segmentation 3: by End-Use Estimates & Trend Analysis
7.1. by End-Use & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-Use:
7.2.1. Clinics
7.2.2. Hospitals
7.2.3. Diagnostics Laboratories
7.2.4. Others
Chapter 8. Liver Disease Management Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Liver Disease Management Market Revenue (US$ Million) Estimates and Forecasts by Diagnosis, 2021-2034
8.1.2. North America Liver Disease Management Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2021-2034
8.1.3. North America Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.1.4. North America Liver Disease Management Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Liver Disease Management Market revenue (US$ Million) by Diagnosis, 2021-2034
8.2.2. Europe Liver Disease Management Market revenue (US$ Million) by Treatment, 2021-2034
8.2.3. Europe Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.2.4. Europe Liver Disease Management Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Liver Disease Management Market revenue (US$ Million) by Diagnosis, 2021-2034
8.3.2. Asia Pacific Liver Disease Management Market revenue (US$ Million) by Treatment, 2021-2034
8.3.3. Asia-Pacific Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.3.4. Asia Pacific Liver Disease Management Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Liver Disease Management Market revenue (US$ Million) by Diagnosis, 2021-2034
8.4.2. Latin America Liver Disease Management Market revenue (US$ Million) by Treatment, 2021-2034
8.4.3. Latin America Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.4.4. Latin America Liver Disease Management Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Liver Disease Management Market revenue (US$ Million) by Diagnosis, 2021-2034
8.5.2. Middle East & Africa Liver Disease Management Market revenue (US$ Million) by Treatment, 2021-2034
8.5.3. Middle East & Africa Liver Disease Management Market revenue (US$ Million) by End-Use, 2021-2034
8.5.4. Middle East & Africa Liver Disease Management Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Abbott
9.2.2. AbbVie Inc.
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.4. Bristol-Myers Squibb Company
9.2.5. Astellas Pharma Inc.
9.2.6. Lilly
9.2.7. Merck & Co., Inc.
9.2.8. Pfizer Inc.
9.2.9. Novartis AG
9.2.10. Johnson & Johnson Private Limited
9.2.11. Other Prominent Players